Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Schenone

Showing results (161-170 of 173) with videos related to

Pageof 18
Sort By:
Journal of Medicinal Chemistry|December 4, 2014
Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastomaCristina Tintori, Anna Lucia Fallacara, Marco Radi, et al.
European Journal of Medicinal Chemistry|November 8, 2012
Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzymeMariangela Biava, Claudio Battilocchio, Giovanna Poce, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|April 15, 2015
SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferationLucia D'Antona, Rosario Amato, Cristina Talarico, et al.
Bioorganic Chemistry|August 6, 2022
Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatmentSalvatore Di Maria, Francesca Picarazzi, Mattia Mori, et al.
Oncotarget|August 28, 2016
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemiaIlaria Laurenzana, Antonella Caivano, Stefania Trino, et al.
Journal of Medicinal Chemistry|June 27, 2017
Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma ModelGiulia Vignaroli, Giulia Iovenitti, Claudio Zamperini, et al.
International Journal of Molecular Sciences|September 27, 2019
Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell LineFrancesco P Cammarata, Filippo Torrisi, Giusi I Forte, et al.
Journal of Medicinal Chemistry|May 27, 2005
Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivativesAngelo Ranise, Andrea Spallarossa, Sara Cesarini, et al.
Journal of Medicinal Chemistry|October 13, 2007
Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in miceFabrizio Manetti, Annalisa Santucci, Giada A Locatelli, et al.
Cancers|June 29, 2019
A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-<i>d</i>]Pyrimidine Dual Src/P-Glycoprotein InhibitorAnna Lucia Fallacara, Claudio Zamperini, Ana Podolski-Renić, et al.
Pageof 18

Showing results (161-170 of 173) with videos related to

Sort By:
Pageof 18
Journal of Medicinal Chemistry|December 4, 2014
Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastomaCristina Tintori, Anna Lucia Fallacara, Marco Radi, et al.
European Journal of Medicinal Chemistry|November 8, 2012
Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzymeMariangela Biava, Claudio Battilocchio, Giovanna Poce, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|April 15, 2015
SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferationLucia D'Antona, Rosario Amato, Cristina Talarico, et al.
Bioorganic Chemistry|August 6, 2022
Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatmentSalvatore Di Maria, Francesca Picarazzi, Mattia Mori, et al.
Oncotarget|August 28, 2016
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemiaIlaria Laurenzana, Antonella Caivano, Stefania Trino, et al.
Journal of Medicinal Chemistry|June 27, 2017
Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma ModelGiulia Vignaroli, Giulia Iovenitti, Claudio Zamperini, et al.
International Journal of Molecular Sciences|September 27, 2019
Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell LineFrancesco P Cammarata, Filippo Torrisi, Giusi I Forte, et al.
Journal of Medicinal Chemistry|May 27, 2005
Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivativesAngelo Ranise, Andrea Spallarossa, Sara Cesarini, et al.
Journal of Medicinal Chemistry|October 13, 2007
Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in miceFabrizio Manetti, Annalisa Santucci, Giada A Locatelli, et al.
Cancers|June 29, 2019
A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-<i>d</i>]Pyrimidine Dual Src/P-Glycoprotein InhibitorAnna Lucia Fallacara, Claudio Zamperini, Ana Podolski-Renić, et al.
Pageof 18